Pulmonx (LUNG)

• Market cap: $244M
• 1 day: -1.12%
• 5 days: -12.69%
• 1 month: -1.12%
• 3 months: -0.80%
• 6 months: -25.96%
• Year to date: -5.06%
• 1 year: -54.08%
• 5 years: -84.25%
• 10 years: -84.25%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Employees: 279

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

22% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 23

21% more capital invested

Capital invested by funds: $249M [Q2] → $301M (+$52.5M) [Q3]

20% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 30

1% more funds holding

Funds holding: 111 [Q2] → 112 (+1) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

7.95% less ownership

Funds ownership: 101.1% [Q2] → 93.15% (-7.95%) [Q3]

100% less call options, than puts

Call options by funds: $10K | Put options by funds: $2.05M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7.50 21% upside
• Avg. target: $10.50 70% upside
• High target: $16 158% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target	29% upside $8	Equal-Weight Maintained	11 Dec 2024
Citigroup Joanne Wuensch 64% 1-year accuracy 30 / 47 met price target	21% upside $7.50	Neutral Downgraded	11 Dec 2024
Stifel Rick Wise 72% 1-year accuracy 21 / 29 met price target	158% upside $16	Buy Maintained	31 Oct 2024